Business Context and Reporting Period
This Form 8-K Current Report was filed by uniQure N.V. on May 17, 2021. The filing discloses the appointment of a new executive officer and details the associated compensatory arrangements. The company is incorporated in The Netherlands and its ordinary shares trade on the Nasdaq Global Select Market under the symbol QURE.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and employment terms rather than financial performance metrics.
Material Changes
The primary material change reported is the appointment of Pierre Caloz as Chief Operations Officer, effective May 17, 2021. Mr. Caloz brings nearly 20 years of global operations experience in the biopharma industry, most recently serving as Senior Vice President and General Manager of European Union and Asia Pacific Operations at CSL Behring.
Compensation, Outlook, and Risks
The filing details the "Caloz Agreement" and a separate letter agreement regarding equity grants:
- Base Salary: CHF 463,760 annually, subject to annual review.
- Target Bonus: Up to 50% of the Base Salary, determined by the Board.
- Sign-on Bonus: CHF 180,103 gross, payable within 30 days of commencement.
- Severance Provisions:
- Termination without cause: Lump sum equal to Base Salary plus Target Bonus.
- Termination within 12 months of a change of control: Lump sum equal to 150% of the sum of Base Salary and Target Bonus.
- Equity Grants (Inducement):
- 25,000 Restricted Stock Units (RSUs) vesting pro-rata over three years.
- Option to purchase 75,000 ordinary shares vesting over four years.
- 10,000 RSUs vesting in full on the first anniversary.
- Change of Control: All equity vesting conditions are automatically waived, and options become fully exercisable for 18 months following a change of control.
The full text of the employment agreement is intended to be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2021.
Investor Verification Checklist
- Verify the final approval of the equity grants by the Board of Directors.
- Review the full text of the Caloz Agreement once filed as an exhibit to the Q2 2021 Form 10-Q.
- Monitor the impact of the new Chief Operations Officer on the company's operational strategy and biopharma pipeline.
- Confirm the currency exchange rates applicable to the CHF-denominated compensation for USD reporting.